Maxim Group reaffirmed their buy rating on shares of Nephros (OTCMKTS:NEPH) in a report issued on Thursday, reports. Maxim Group currently has a $16.00 price target on the stock.

A number of other research firms have also recently issued reports on NEPH. Benchmark initiated coverage on shares of Nephros in a research note on Thursday, October 24th. They issued a buy rating and a $16.00 price target on the stock. Zacks Investment Research raised shares of Nephros from a hold rating to a buy rating and set a $12.00 price target on the stock in a research note on Friday, October 18th.

Shares of OTCMKTS:NEPH traded up $0.97 during trading on Thursday, hitting $9.00. 23,603 shares of the stock traded hands, compared to its average volume of 7,750. The company has a quick ratio of 1.86, a current ratio of 2.56 and a debt-to-equity ratio of 0.26. The company has a market cap of $61.61 million, a price-to-earnings ratio of -16.67 and a beta of 0.85. The company has a fifty day moving average price of $9.11 and a two-hundred day moving average price of $4.79. Nephros has a 52-week low of $3.69 and a 52-week high of $11.35.

Nephros (OTCMKTS:NEPH) last posted its earnings results on Wednesday, November 6th. The company reported ($0.10) earnings per share for the quarter, meeting the consensus estimate of ($0.10). The firm had revenue of $3.10 million during the quarter, compared to analyst estimates of $3.12 million. Nephros had a negative net margin of 49.93% and a negative return on equity of 56.37%. On average, equities research analysts predict that Nephros will post -0.63 EPS for the current fiscal year.

Nephros Company Profile

Nephros, Inc, a commercial stage medical device and commercial product company, develops and sells liquid purification filters and hemodiafiltration (HDF) systems primarily in the United States. It operates through two segments, Water Filtration and Renal Products. The company's ultrafilters are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from water borne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities.

Read More: Mutual funds are not immune from market timing

Receive News & Ratings for Nephros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nephros and related companies with's FREE daily email newsletter.